TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. TESARO is a clinical stage, oncology-focused biopharmaceutical company and companys pipeline is sourced through business development and licensing activities.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”TSRO” api=”yf” style=”font-size: 15px”]
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/tesaro” connections=”true” suffix=””]
In Mar 2014, AnaptysBio granted TESARO an exclusive rights to its antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. TESARO paid $17 Mn upfront payment and up to $90 Mn in milestones for approval–on each program.
In Jun 2012, TESARO in-licensed Niraparib/MK-4827, being evaluated in PH I for treatment of solid tumors, from Merck. In Mar 2011, TESARO in-licensed small molecule inhibitors of Anaplastic Lymphoma Kinase (ALK) program from Amgen.
In Dec 2010, TESARO in-licensed worldwide rights to Its lead compound – Rolapitant, currently undergoing PH III for the treatment of chemotherapy induced nausea and vomiting, from OPKO Health, Inc.
Key investors include New Enterprise Associates, InterWest Partners, Kleiner Perkins Caufield & Byers, Venrock, Pappas Ventures, T. Rowe Price, Oracle Partners, Deerfield Management and Leerink Swann.